Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Deferred Revenue: 2016-2023

Historic Current Deferred Revenue for Fortress Biotech (FBIO) over the last 4 years, with Mar 2023 value amounting to $547,000.

  • Fortress Biotech's Current Deferred Revenue fell 73.11% to $547,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $547,000, marking a year-over-year decrease of 73.11%. This contributed to the annual value of $728,000 for FY2022, which is 72.12% down from last year.
  • Fortress Biotech's Current Deferred Revenue amounted to $547,000 in Q1 2023, which was down 24.86% from $728,000 recorded in Q4 2022.
  • Over the past 5 years, Fortress Biotech's Current Deferred Revenue peaked at $7.2 million during Q1 2021, and registered a low of $547,000 during Q1 2023.
  • Its 3-year average for Current Deferred Revenue is $2.6 million, with a median of $2.0 million in 2022.
  • Data for Fortress Biotech's Current Deferred Revenue shows a maximum YoY crashed of 73.11% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then tumbled by 72.12% to $728,000 in 2022, then crashed by 73.11% to $547,000 in 2023.
  • Its Current Deferred Revenue was $547,000 in Q1 2023, compared to $728,000 in Q4 2022 and $1.1 million in Q3 2022.